Lista de obras -

Abstract P3-02-06: A phase II study of 68Ga-ABY-025 PET for non-invasive quantification of HER2 expression in breast cancer

scientific article published in 2022

Affibody Molecules in Biotechnological and Medical Applications

artículo científico publicado en 2017

Affibody molecules as engineered protein drugs

artículo científico publicado en 2017

Affibody molecules for epidermal growth factor receptor targeting in vivo: aspects of dimerization and labeling chemistry

artículo científico publicado en 2009

Affibody-Mediated Sequestration of Amyloid β Demonstrates Preventive Efficacy in a Transgenic Alzheimer's Disease Mouse Model

scholarly article by Allal Boutajangout et al published 2019 in Frontiers in Aging Neuroscience

An affibody-adalimumab hybrid blocks combined IL-6 and TNF-triggered serum amyloid A secretion in vivo

artículo científico publicado en 2014

An engineered affibody molecule with pH-dependent binding to FcRn mediates extended circulatory half-life of a fusion protein

artículo científico publicado en 2014

Bispecific Affibody Molecules for Targeting of EGFR and HER2

CAIX-targeting radiotracers for hypoxia imaging in head and neck cancer models

scientific article published on 11 December 2019

Cellular effects of HER3-specific affibody molecules

artículo científico publicado en 2012

Combining phage and staphylococcal surface display for generation of ErbB3-specific Affibody molecules.

artículo científico publicado en 2010

Comparative Evaluation of Affibody Molecules for Radionuclide Imaging of in Vivo Expression of Carbonic Anhydrase IX.

artículo científico publicado en 2016

Comparative evaluation of affibody- and antibody fragments-based CAIX imaging probes in mice bearing renal cell carcinoma xenografts

artículo científico publicado en 2019

Correction: Inhibiting HER3-Mediated Tumor Cell Growth with Affibody Molecules Engineered to Low Picomolar Affinity by Position-Directed Error-Prone PCR-Like Diversification.

artículo científico publicado en 2013

Diagnostic HER2-binding radiopharmaceutical, [Ga]Ga-ABY-025, for routine clinical use in breast cancer patients

Dimeric HER2-specific affibody molecules inhibit proliferation of the SKBR-3 breast cancer cell line

artículo científico publicado en 2008

Engineering and characterization of a bispecific HER2 x EGFR-binding affibody molecule

artículo científico publicado en 2009

Engineering of a bispecific affibody molecule towards HER2 and HER3 by addition of an albumin-binding domain allows for affinity purification and in vivo half-life extension.

artículo científico publicado en 2014

Evaluation of the Therapeutic Potential of a HER3-Binding Affibody Construct TAM-HER3 in Comparison with a Monoclonal Antibody, Seribantumab

artículo científico publicado en 2018

Generation and evaluation of bispecific affibody molecules for simultaneous targeting of EGFR and HER2.

artículo científico publicado en 2012

Generation of tumour-necrosis-factor-alpha-specific affibody molecules capable of blocking receptor binding in vitro

artículo científico publicado en 2009

Imaging of CAIX-expressing xenografts in vivo using 99mTc-HEHEHE-ZCAIX:1 affibody molecule

artículo científico publicado en 2014

Imaging of platelet-derived growth factor receptor β expression in glioblastoma xenografts using affibody molecule 111In-DOTA-Z09591.

artículo científico publicado en 2014

Imaging using radiolabelled targeted proteins: radioimmunodetection and beyond

artículo científico publicado en 2020

In Vitro Characterization of 177Lu-DOTA-M5A Anti-Carcinoembryonic Antigen Humanized Antibody and HSP90 Inhibition for Potentiated Radioimmunotherapy of Colorectal Cancer

artículo científico publicado en 2022

In Vivo Evaluation and Dosimetry Estimate for a High Affinity Affibody PET Tracer Targeting PD-L1

artículo científico publicado en 2020

In vivo Imaging of the Programmed Death Ligand 1 by (18)F Positron Emission Tomography

artículo científico

In vivo depletion of serum IgG by an affibody molecule binding the neonatal Fc receptor.

artículo científico publicado en 2018

In vivo evaluation of a novel format of a bivalent HER3-targeting and albumin-binding therapeutic affibody construct.

artículo científico publicado en 2017

Influence of valency and labelling chemistry on in vivo targeting using radioiodinated HER2-binding Affibody molecules.

artículo científico publicado en 2008

Inhibiting HER3-mediated tumor cell growth with affibody molecules engineered to low picomolar affinity by position-directed error-prone PCR-like diversification

artículo científico publicado en 2013

Kinetic analysis of HER2-binding ABY-025 Affibody molecule using dynamic PET in patients with metastatic breast cancer

scientific article published on 23 March 2020

Non-immunoglobulin based protein scaffolds.

scientific article published on 02 July 2011

Quantification of internalization of EGFR-binding Affibody molecules: Methodological aspects

artículo científico publicado en 2010

Same-Day Imaging Using Small Proteins: Clinical Experience and Translational Prospects in Oncology

artículo científico publicado en 2018

Simultaneous targeting of two ligand-binding sites on VEGFR2 using biparatopic Affibody molecules results in dramatically improved affinity

artículo científico publicado en 2014

Site-specific radiometal labeling and improved biodistribution using ABY-027, a novel HER2-targeting affibody molecule-albumin-binding domain fusion protein.

artículo científico publicado en 2013

Target-specific cytotoxic effects on HER2-expressing cells by the tripartite fusion toxin ZHER2:2891-ABD-PE38X8, including a targeting affibody molecule and a half-life extension domain.

artículo científico publicado en 2015

Targeting HER3 using mono- and bispecific antibodies or alternative scaffolds.

artículo científico publicado en 2016

Targeting of epidermal growth factor receptor (EGFR)-expressing tumor cells with sterically stabilized affibody liposomes (SAL).

artículo científico publicado en 2009

Lista de obras de

Abstract P3-02-06: A phase II study of 68Ga-ABY-025 PET for non-invasive quantification of HER2 expression in breast cancer

Affibody Molecules in Biotechnological and Medical Applications

Affibody molecules as engineered protein drugs

Affibody molecules for epidermal growth factor receptor targeting in vivo: aspects of dimerization and labeling chemistry

Affibody-Mediated Sequestration of Amyloid β Demonstrates Preventive Efficacy in a Transgenic Alzheimer's Disease Mouse Model

An affibody-adalimumab hybrid blocks combined IL-6 and TNF-triggered serum amyloid A secretion in vivo

An engineered affibody molecule with pH-dependent binding to FcRn mediates extended circulatory half-life of a fusion protein

Bispecific Affibody Molecules for Targeting of EGFR and HER2

CAIX-targeting radiotracers for hypoxia imaging in head and neck cancer models

Cellular effects of HER3-specific affibody molecules

Combining phage and staphylococcal surface display for generation of ErbB3-specific Affibody molecules.

Comparative Evaluation of Affibody Molecules for Radionuclide Imaging of in Vivo Expression of Carbonic Anhydrase IX.

Comparative evaluation of affibody- and antibody fragments-based CAIX imaging probes in mice bearing renal cell carcinoma xenografts

Correction: Inhibiting HER3-Mediated Tumor Cell Growth with Affibody Molecules Engineered to Low Picomolar Affinity by Position-Directed Error-Prone PCR-Like Diversification.

Diagnostic HER2-binding radiopharmaceutical, [Ga]Ga-ABY-025, for routine clinical use in breast cancer patients

Dimeric HER2-specific affibody molecules inhibit proliferation of the SKBR-3 breast cancer cell line

Engineering and characterization of a bispecific HER2 x EGFR-binding affibody molecule

Engineering of a bispecific affibody molecule towards HER2 and HER3 by addition of an albumin-binding domain allows for affinity purification and in vivo half-life extension.

Evaluation of the Therapeutic Potential of a HER3-Binding Affibody Construct TAM-HER3 in Comparison with a Monoclonal Antibody, Seribantumab

Generation and evaluation of bispecific affibody molecules for simultaneous targeting of EGFR and HER2.

Generation of tumour-necrosis-factor-alpha-specific affibody molecules capable of blocking receptor binding in vitro

Imaging of CAIX-expressing xenografts in vivo using 99mTc-HEHEHE-ZCAIX:1 affibody molecule

Imaging of platelet-derived growth factor receptor β expression in glioblastoma xenografts using affibody molecule 111In-DOTA-Z09591.

Imaging using radiolabelled targeted proteins: radioimmunodetection and beyond

In Vitro Characterization of 177Lu-DOTA-M5A Anti-Carcinoembryonic Antigen Humanized Antibody and HSP90 Inhibition for Potentiated Radioimmunotherapy of Colorectal Cancer

In Vivo Evaluation and Dosimetry Estimate for a High Affinity Affibody PET Tracer Targeting PD-L1

In vivo Imaging of the Programmed Death Ligand 1 by (18)F Positron Emission Tomography

In vivo depletion of serum IgG by an affibody molecule binding the neonatal Fc receptor.

In vivo evaluation of a novel format of a bivalent HER3-targeting and albumin-binding therapeutic affibody construct.

Influence of valency and labelling chemistry on in vivo targeting using radioiodinated HER2-binding Affibody molecules.

Inhibiting HER3-mediated tumor cell growth with affibody molecules engineered to low picomolar affinity by position-directed error-prone PCR-like diversification

Kinetic analysis of HER2-binding ABY-025 Affibody molecule using dynamic PET in patients with metastatic breast cancer

Non-immunoglobulin based protein scaffolds.

Quantification of internalization of EGFR-binding Affibody molecules: Methodological aspects

Same-Day Imaging Using Small Proteins: Clinical Experience and Translational Prospects in Oncology

Simultaneous targeting of two ligand-binding sites on VEGFR2 using biparatopic Affibody molecules results in dramatically improved affinity

Site-specific radiometal labeling and improved biodistribution using ABY-027, a novel HER2-targeting affibody molecule-albumin-binding domain fusion protein.

Target-specific cytotoxic effects on HER2-expressing cells by the tripartite fusion toxin ZHER2:2891-ABD-PE38X8, including a targeting affibody molecule and a half-life extension domain.

Targeting HER3 using mono- and bispecific antibodies or alternative scaffolds.

Targeting of epidermal growth factor receptor (EGFR)-expressing tumor cells with sterically stabilized affibody liposomes (SAL).